Compare Definium Therapeutics Inc. Common Shares (DFTX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs UiPath Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.9 (market cap $4.59B), while UiPath Inc trades at $13.48 (market cap $6.91B). The key difference: UiPath Inc is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and UiPath Inc for 139 Days on average.
| DFTX | PATH | |
|---|---|---|
Market Cap | $4.59B | $6.91B |
Volume | 2,103,937 | 34,321,250 |
Sector | Health | Technology |
52-Week High | $48.45 | $19.29 |
52-Week Low | $10.68 | $9.38 |
Typical Hold Time | 0 Days | 139 Days |
Enterprise Value | $3.55B | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UiPath (PATH) trades at $13.48, up 3.14% today, showing technical bullish momentum despite mixed earnings results. The company demonstrates strong revenue growth from $892M in 2022 to $1.43B in 2025, with improving profit margins turning positive in 2026. Recent partnerships with Snowflake and BDO highlight expansion in AI orchestration capabilities, while analyst sentiment remains cautious with 67% hold ratings.
PATH offers growth potential through enterprise automation leadership and AI integration, but faces execution risks and competitive pressure. The stock trades below consensus price target of $15.13, representing 12% upside, though negative cash flow trends and valuation concerns warrant careful monitoring of quarterly execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
